Last 12 months
Inside the activity.
0 purchase rows · 19 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 08, 2021 Filed Apr 9, 2021 20:27 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
SaleCommon Stock | 6,600 | $132.85 | $876,810.00 |
DisclosureSEC source: 0001127602-21-013563 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 20:27 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
Exercise / conversionCommon Stock | 6,600 | $20.93 | $138,138.00 |
DisclosureSEC source: 0001127602-21-013563 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 20:15 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $132.85 | $1,328,500.00 |
DisclosureSEC source: 0001127602-21-013557 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,464,880 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019. F5 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 20:11 UTC |
Andres JuanSee remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-013484 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,822 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 20:11 UTC |
Andres JuanSee remarks
|
SaleCommon Stock | 5,000 | $131.63 | $658,150.00 |
DisclosureSEC source: 0001127602-21-013484 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 20:11 UTC |
Andres JuanSee remarks
|
Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-013484 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 20:15 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-013557 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,367,868 F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended December 23, 2020. F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 20:15 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,000 | $131.63 | $1,184,670.00 |
DisclosureSEC source: 0001127602-21-013557 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,369,868 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:09 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-21-013482 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,876 Underlying: Common Stock · 6,600 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:09 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
SaleCommon Stock | 6,600 | $130.01 | $858,066.00 |
DisclosureSEC source: 0001127602-21-013482 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 20:09 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
Exercise / conversionCommon Stock | 6,600 | $20.93 | $138,138.00 |
DisclosureSEC source: 0001127602-21-013482 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:07 UTC |
Hoge StephenPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-21-013337 · form4.xml · derivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:07 UTC |
Hoge StephenPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-21-013337 · form4.xml · derivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:07 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 20,000 | $132.63 | $2,652,600.00 |
DisclosureSEC source: 0001127602-21-013337 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609,597 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:07 UTC |
Hoge StephenPresident
|
Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-21-013337 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,629,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:07 UTC |
Hoge StephenPresident
|
Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-21-013337 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,619,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:13 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-013342 · form4.xml · derivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,282 Underlying: Common Stock · 5,000 shares Expires 2027-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · derivative.exercise_date: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:13 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 1,150 | $130.95 | $150,592.50 |
DisclosureSEC source: 0001127602-21-013342 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.58 to $131.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:13 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 2,426 | $129.96 | $315,282.96 |
DisclosureSEC source: 0001127602-21-013342 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,574 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.47 to $130.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:13 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 814 | $128.65 | $104,721.10 |
DisclosureSEC source: 0001127602-21-013342 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.33 to $129.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:13 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 610 | $127.76 | $77,933.60 |
DisclosureSEC source: 0001127602-21-013342 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,964 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.21 to $128.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:13 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-013342 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:11 UTC |
Andres JuanSee remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-013340 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,822 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:11 UTC |
Andres JuanSee remarks
|
SaleCommon Stock | 5,000 | $132.63 | $663,150.00 |
DisclosureSEC source: 0001127602-21-013340 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:11 UTC |
Andres JuanSee remarks
|
Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-013340 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:05 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 100 | $132.73 | $13,273.00 |
DisclosureSEC source: 0001127602-21-013334 · form4.xml · nonDerivative · entry 5 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 88,384 F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:05 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 2,533 | $130.97 | $331,747.01 |
DisclosureSEC source: 0001127602-21-013334 · form4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 88,484 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.52 to $131.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:05 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 5,157 | $130.00 | $670,410.00 |
DisclosureSEC source: 0001127602-21-013334 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 91,017 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.51 to $130.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:05 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 2,131 | $128.72 | $274,302.32 |
DisclosureSEC source: 0001127602-21-013334 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 96,174 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.33 to $129.32. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:05 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 1,125 | $127.72 | $143,685.00 |
DisclosureSEC source: 0001127602-21-013334 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 98,305 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.17 to $128.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 14:34 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $132.51 | $1,325,100.00 |
DisclosureSEC source: 0001127602-21-012676 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,474,880 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019. F5 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 14:30 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-21-012672 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,476 Underlying: Common Stock · 6,600 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 14:30 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
SaleCommon Stock | 6,600 | $132.51 | $874,566.00 |
DisclosureSEC source: 0001127602-21-012672 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 14:30 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
Exercise / conversionCommon Stock | 6,600 | $20.93 | $138,138.00 |
DisclosureSEC source: 0001127602-21-012672 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 00:00 UTC |
Afeyan NoubarDirector
|
SaleCommon Stock | 4,888 | $121.07 | $591,809.71 |
DisclosureSEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 18 AFEYAN NOUBAR · CIK 0001222012 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Disclosed balance after: 9,116,657 F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans. F20 · shares: Represents 4,106 shares sold by Flagship Fund IV and 782 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.90 to $121.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F20 · price: Represents 4,106 shares sold by Flagship Fund IV and 782 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.90 to $121.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F21 · balance_after: Following the transactions reported herein, 5,791,562 shares are held directly by Flagship Fund IV and 3,325,095 shares are held directly by Flagship Fund IV-Rx. F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:17 UTC |
Andres JuanSee remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-21-012584 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,822 Underlying: Common Stock · 5,000 shares Expires 2027-08-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:17 UTC |
Andres JuanSee remarks
|
SaleCommon Stock | 5,000 | $121.10 | $605,500.00 |
DisclosureSEC source: 0001127602-21-012584 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:17 UTC |
Andres JuanSee remarks
|
Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-21-012584 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 14:34 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-012676 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,378,868 F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended December 23, 2020. F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 14:34 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,000 | $121.10 | $1,089,900.00 |
DisclosureSEC source: 0001127602-21-012676 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,380,868 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 00:00 UTC |
Afeyan NoubarDirector
|
SaleCommon Stock | 1,000 | $123.44 | $123,440.00 |
DisclosureSEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 17 AFEYAN NOUBAR · CIK 0001222012 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Disclosed balance after: 9,121,545 F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans. F19 · shares: Represents 840 shares sold by Flagship Fund IV and 160 shares sold by Flagship Fund IV-Rx. F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 00:00 UTC |
Afeyan NoubarDirector
|
SaleCommon Stock | 31,943 | $123.08 | $3,931,538.05 |
DisclosureSEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 16 AFEYAN NOUBAR · CIK 0001222012 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Disclosed balance after: 9,122,545 F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans. F18 · shares: Represents 26,832 shares sold by Flagship Fund IV and 5,111 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.40 to $123.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F18 · price: Represents 26,832 shares sold by Flagship Fund IV and 5,111 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.40 to $123.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 00:00 UTC |
Afeyan NoubarDirector
|
SaleCommon Stock | 14,379 | $121.71 | $1,750,037.89 |
DisclosureSEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 15 AFEYAN NOUBAR · CIK 0001222012 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Disclosed balance after: 9,154,488 F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans. F17 · shares: Represents 12,079 shares sold by Flagship Fund IV and 2,300 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.40 to $122.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F17 · price: Represents 12,079 shares sold by Flagship Fund IV and 2,300 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.40 to $122.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 00:00 UTC |
Afeyan NoubarDirector
|
SaleCommon Stock | 225,732 | $120.76 | $27,259,283.45 |
DisclosureSEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 14 AFEYAN NOUBAR · CIK 0001222012 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Disclosed balance after: 9,168,867 F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans. F16 · shares: Represents 189,615 shares sold by Flagship Fund IV and 36,117 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.40 to $121.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F16 · price: Represents 189,615 shares sold by Flagship Fund IV and 36,117 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.40 to $121.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 00:00 UTC |
Afeyan NoubarDirector
|
SaleCommon Stock | 344,542 | $119.81 | $41,278,061.04 |
DisclosureSEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 13 AFEYAN NOUBAR · CIK 0001222012 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Disclosed balance after: 9,394,599 F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans. F15 · shares: Represents 289,415 shares sold by Flagship Fund IV and 55,127 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.40 to $120.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F15 · price: Represents 289,415 shares sold by Flagship Fund IV and 55,127 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.40 to $120.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 00:00 UTC |
Afeyan NoubarDirector
|
SaleCommon Stock | 611,922 | $118.90 | $72,758,504.88 |
DisclosureSEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 12 AFEYAN NOUBAR · CIK 0001222012 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Disclosed balance after: 9,739,141 F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans. F14 · shares: Represents 514,014 shares sold by Flagship Fund IV and 97,908 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.40 to $119.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F14 · price: Represents 514,014 shares sold by Flagship Fund IV and 97,908 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.40 to $119.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 00:00 UTC |
Afeyan NoubarDirector
|
SaleCommon Stock | 883,277 | $118.04 | $104,265,815.17 |
DisclosureSEC source: 0001209191-21-023877 · doc4.xml · nonDerivative · entry 11 AFEYAN NOUBAR · CIK 0001222012 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Disclosed balance after: 10,351,063 F1 · kind: These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020 (the "Plans"). Following the reported transactions, there are no shares remaining to be sold under these Plans. F13 · shares: Represents 741,953 shares sold by Flagship Fund IV and 141,324 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.40 to $118.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F13 · price: Represents 741,953 shares sold by Flagship Fund IV and 141,324 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.40 to $118.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 20:22 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-21-012597 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,076 Underlying: Common Stock · 6,600 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 20:22 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
SaleCommon Stock | 6,600 | $123.30 | $813,780.00 |
DisclosureSEC source: 0001127602-21-012597 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 20:22 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
Exercise / conversionCommon Stock | 6,600 | $20.93 | $138,138.00 |
DisclosureSEC source: 0001127602-21-012597 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.